FDA Inspection
Altaire Pharmaceuticals, Inc.Altaire Pharmaceuticals, Inc. – FDA Inspection, Feb 11, 2022
Record Details
This FDA Inspection record concerns Altaire Pharmaceuticals, Inc., with an inspection on February 11, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- February 11, 2022
- Product Type
- Drugs
View Company Profile
ID · 0c20c70c-b178-4306-8b90-55ba5c3ee376
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1162640
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of Altaire Pharmaceuticals, Inc.
13| Date | Classification | Office | Project area |
|---|---|---|---|
| April 21, 2026 | Not classified | New York District Office | Drug Quality Assurance |
| October 21, 2024 | NAI | Center for Devices and Radiological Health | Compliance: Devices |
| April 19, 2019 | OAI | Center for Veterinary Medicine | Generic Drug Evaluation |
| March 9, 2017 | VAI | Center for Veterinary Medicine | Monitoring of Marketed Animal Drugs, Feed, and Devices |
| December 15, 2015 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Altaire Pharmaceuticals, Inc.
- FDA Inspection 1314330 - 2026-04-21
- FDA Inspection 1251507 - 2024-10-21
- FDA Inspection 1089315 - 2019-04-19
- FDA Inspection 1005208 - 2017-03-09
- FDA Inspection 955795 - 2015-12-15
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.